BRIEF-Galena Biopharma says combination of trastuzumab and NeuVax in HER2 low-expressing patients is well-tolerated
Oct 10 Galena Biopharma Inc :
* Galena Biopharma Inc - combination of trastuzumab and neuvax in HER2 low-expressing (le) patients is well-tolerated
* Galena Biopharma Inc - cardiac effects of trastuzumab are not impacted by addition of NeuVax
* Galena Biopharma Inc - there was one CG patient who experienced a grade 3 cardiac adverse event during trial
* Galena Biopharma- after 12 months of follow-up combination of trastuzumab and neuvax , co expects to report first interim efficacy,immunologic outcomes at end of 2017 Source text for Eikon: Further company coverage:
AT&T reaches deal to buy Time Warner for more than $80 billion -WSJ
Oct 22 AT&T Inc reached a deal to buy media company Time Warner Inc for more than $80 billion, The Wall Street Journal reported on Saturday.
Trump vows to weaken U.S. media 'power structure' if elected
GETTSYBURG, Pa. , Oct 22 U.S. Republican presidential candidate Donald Trump promised on Saturday to foil a proposed deal for AT&T Inc to buy Time Warner Inc if he wins the Nov. 8 election, arguing it was an example of a "power structure" rigged against both him and voters.